China Pharma Holdings (CPHI) Retained Earnings (2010 - 2026)

China Pharma Holdings (CPHI) has reported Retained Earnings for 17 consecutive years, with $73.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 262.12% year-over-year to $73.5 million; the trailing twelve-month figure through Jun 2026 stood at $73.5 million (up 262.12% YoY), and the FY2025 full-year result was $58.5 million, up 232.96% from the prior year.
• Retained Earnings steadied at $73.5 million in Q2 2026 per CPHI's latest filing, from $73.5 million in the prior quarter.
• Across five years, Retained Earnings topped out at $73.5 million in Q1 2026 and bottomed at -$46.0 million in Q3 2025.
• Historically, Retained Earnings has averaged -$5.9 million across 5 years, with a median of -$37.2 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Retained Earnings slumped 211.75% in 2024, then jumped 264.03% in 2026.
• Over 5 years, Retained Earnings stood at -$36.2 million in 2022, then retreated by 8.5% to -$39.3 million in 2023, then retreated by 12.05% to -$44.0 million in 2024, then surged by 232.96% to $58.5 million in 2025, then grew by 25.57% to $73.5 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $73.5 million, $73.5 million, and $58.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.